Clinical trials
5 active studies led by Generate Biomedicines, of 6 in all
Source: ClinicalTrials.gov, Studies with Generate Biomedicines (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 3Markets in public records
- 0Regions & countries
- 5Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by Generate Biomedicines or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on Generate Biomedicines
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Company facts
- Stock listing
- NASDAQ: GENB
- Type
- Medicines
Source: SEC EDGAR, Company filings, CIK 2100782. Retrieved 13 Nov 2026.
See them on ClinicalTrials.gov (opens in a new tab)
SEC filings
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 2100782.
Trials over time
Studies Generate Biomedicines leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with Generate Biomedicines or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show Generate Biomedicines: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets Generate Biomedicines is in.
From our blog
Stories on the topics Generate Biomedicines works in.
Patient Support Programmes: Helping Patients Stay on Treatment
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Airway Management Devices: Critical Tools in Emergencies
Keeping the airway open is the first step in saving a life. More than half of deaths in low- and…
Read
Anaesthesia and Respiratory Devices: Lessons After COVID
More than 5 billion people lack access to safe, affordable medical oxygen. COVID-19 exposed gaps in…
Read